To be eligible for the trial, patients were required to have stage 1 to 3 triple-negative or BRCA-mutated, hormone receptor ...

Black women experience advanced diagnoses 55% more often than white women and are more likely to die from the disease, the ...

It’s been long known that women with BRCA1 and BRCA2 gene mutations are at higher risk for breast and ovarian cancer. More ...

AstraZeneca & Merck announce OlympiA phase 3 trial of Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer: Rahway, New Jersey Friday, Dec ...

Women with a type of low-risk cancer might not have to rush aggressive treatment, doctors say.

Precision medicine is an innovative approach that tailors treatment to the unique genetic and molecular characteristics of a ...

The future of breast cancer screening and risk-reducing strategies is being shaped by artificial intelligence (AI), according to a recent review article.

RISK-REDUCING surgeries, including bilateral mastectomy (RRM) and salpingo-oophorectomy (RRSO), are associated with improved ...

More than 100 000 women older than 70 years are diagnosed with hormone receptor-positive, early-stage breast cancer each year in the USA.1 A large proportion are at low risk of disease recurrence, ...

Among more than 5,000 patients followed for a median of roughly 8 years, bilateral risk-reducing mastectomy (RRM) was ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.